Janux Therapeutics, Inc. (JANX) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
11099 North Torrey Pines Road
San Diego, CA 92037
United States of America (the)
Phone
858 750 4700
Website
Sector
Healthcare
Industry
Biotechnology
Employees
91
First IPO Date
June 11, 2021
| Name | Title | Pay | Year Born |
| David Alan Campbell | President, Co-Founder, CEO & Director | 1.05M | 1960 |
| Janeen Doyle | Chief Corporate & Business Development Officer | 549,029 | 1978 |
| Charles Winter | Chief Technical Officer | 590,400 | 1969 |
| William Y. Go | Chief Medical Officer | 626,400 | 1976 |
| Thomas Diraimondo | Chief Scientific Officer | 653,904 | 1986 |
| James Pennington | General Counsel & Corporate Secretary | 0 | N/A |
| Matt Whitmire | Vice President of Finance | 0 | N/A |
| Maria Dobek | Vice President of Accounting | 0 | 1990 |
Janux Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative cancer therapies. The firm leverages its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to create treatments designed to activate the body's T cells to fight tumors. Currently, Janux has several promising TRACTr product candidates in their early preclinical or discovery stages, which are engineered to target specific antigens such as prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. In addition to its TRACTr pipeline, the company is also developing a Tumor Activated Immunomodulator (TRACIr) — a costimulatory bispecific candidate designed to enhance T cell anti-tumor activity by engaging with programmed death-ligand 1 and CD28. Furthermore, a specific focus for their EGFR-TRACTr program is addressing epidermal growth factor receptor, a target prevalent in many cancer types and already a focus of numerous approved monoclonal antibody treatments. Janux Therapeutics, Inc. was founded in 2017 and is headquartered in La Jolla, California.